My ePortfolio Register   

ESMO ranking of the clinical benefits of new drugs

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.06.17
Views: 373

Prof Alberto Sobrero - Ospedale San Martino, Genova, Italy

Prof Sobrero talks to ecancer at IFCPE 2017 about the way that ESMO manages and ranks the clinical benefits of new drugs in order to help with prescription.

He goes on to talk about his paper that highlights some of the problems with the scale due to the narrow criteria observed when ranking new drugs.

The past 5 years of drug approvals were also discussed by Prof Filippo de Braud, here.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence